# Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

> **NCT01030861** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 76 (actual)

## Conditions studied

- Autoantibody Positive
- Non-diabetic Relatives at Risk for Type 1 Diabetes
- High Risk
- Impaired Glucose Tolerance

## Interventions

- **DRUG:** Teplizumab
- **DRUG:** Placebo infusion

## Key facts

- **NCT ID:** NCT01030861
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2018-11
- **Final completion:** 2019-06
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2020-08-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01030861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01030861, "Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01030861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*